Compare Main Street Capital Corporation (MAIN) vs Novartis AG (NVS) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
Main Street Capital Corporation vs Novartis AG — how do they compare? Main Street Capital Corporation trades at $54.6 (market cap $5.08B), while Novartis AG trades at $153.88 (market cap $290.25B). The key difference: Novartis AG is far larger — about 57.1× Main Street Capital Corporation's market cap, and Main Street Capital Corporation pays the higher dividend (8.02%). Which is the better fit depends on your goals.
| MAIN | NVS | |
|---|---|---|
Market Cap | $5.08B | $290.25B |
Sector | Financials | Health |
52-Week High | $67.54 | $168.62 |
52-Week Low | $49.63 | $113.50 |
Dividend Yield | 8.02% | 3.17% |
Enterprise Value | — | $330.27B |
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
Top news
Latest headlines on both assets
Top news
Latest headlines on both assets
About Main Street Capital Corporation
Main Street Capital Corp is an investment firm engaged in providing customized debt and equity financing to lower middle market companies and debt capital to middle market companies. The investment portfolio of the company is typically made to support management buyouts, recapitalizations, growth financings, refinancings and acquisitions of companies that operate in diverse industry sectors. The group invests in secured debt investments, equity investments, warrants and other securities of the lower middle market and middle market companies based in the US. Business is functioned through the U.S region and it derives the majority of the income from the source of fee, commission, and interest.
Read more on MAIN →About Novartis AG
Novartis develops and manufactures healthcare products through two segments: Innovative Medicines and Sandoz. It generates the vast majority of its revenue from Innovative Medicines segment consisting global business franchises in oncology, ophthalmology, neuroscience, immunology, respiratory, cardio-metabolic, and established medicines. The company sells its products globally, with the United States representing close to one third of total revenue.
Read more on NVS →
